Skip to main content
Top
Published in: Tumor Biology 1/2014

01-01-2014 | Research Article

TRAF6 promoted the metastasis of esophageal squamous cell carcinoma

Authors: Qingqi Han, Feng Yao, Chenxi Zhong, Heng Zhao

Published in: Tumor Biology | Issue 1/2014

Login to get access

Abstract

Esophageal cancer is one of the most aggressive malignancies and has been ranked as the sixth leading cause of cancer-related death in the world. It is very urgent to find new therapeutic targets. Although tumor necrosis factor receptor-associated factor 6 (TRAF6) was initially identified as an adaptor for NF-κB signaling, recently it has been found to be involved in cancer by modulating various signaling pathways. In the previous study, we have found that TRAF6 promoted the growth of esophageal squamous cell carcinoma (ESCC) cell in vitro and in vivo. However, the effects of TRAF6 on the migration and metastasis of ESCC cells are poorly understood. Here, we found that TRAF6 promoted migration and metastasis of ESCC cells through modulating Ras signaling. Overexpression of TRAF6 promoted the migration of ESCC cells and immortalized esophageal epithelial cells, while knock down the expression of TRAF6 inhibited the migration and metastasis of ESCC cells in vitro and in vivo. Mechanically, TRAF6 binds Ras with its N-terminal and activated Ras signaling. Taken together, TRAF6 played an important role in the metastasis of ESCC and might be a promising therapeutic target.
Literature
1.
go back to reference Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:S4–66.PubMedCrossRef Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:S4–66.PubMedCrossRef
3.
go back to reference Zhang WH, Li WD, Wang XQ, et al. Segregation analysis of esophageal cancer in a moderately high incidence area of northern China. Am J Human Genet. 2000;67:110–9.CrossRef Zhang WH, Li WD, Wang XQ, et al. Segregation analysis of esophageal cancer in a moderately high incidence area of northern China. Am J Human Genet. 2000;67:110–9.CrossRef
4.
go back to reference Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRef
5.
go back to reference He LR, Liu MZ, Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009;100:1591–6.PubMedCrossRef He LR, Liu MZ, Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009;100:1591–6.PubMedCrossRef
6.
go back to reference Yuen HF, Chan YP, Law S, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3593–602.PubMedCrossRef Yuen HF, Chan YP, Law S, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3593–602.PubMedCrossRef
7.
go back to reference Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527–33.PubMedCrossRef Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527–33.PubMedCrossRef
8.
9.
go back to reference Ioannis DL, Stavroula B, Ioannis B, Elias K, Demetrios AS. K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res. 2008;14:267–73.CrossRef Ioannis DL, Stavroula B, Ioannis B, Elias K, Demetrios AS. K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res. 2008;14:267–73.CrossRef
10.
go back to reference Inoue J, Gohda J, Akiyama T. Characteristics and biological functions of TRAF6. Adv Exp Med Biol. 2007;597:72–9.PubMedCrossRef Inoue J, Gohda J, Akiyama T. Characteristics and biological functions of TRAF6. Adv Exp Med Biol. 2007;597:72–9.PubMedCrossRef
12.
go back to reference Daniel TS, William WL, Sophie D. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Investig. 2011;121:4095–105.CrossRef Daniel TS, William WL, Sophie D. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Investig. 2011;121:4095–105.CrossRef
13.
go back to reference Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol. 2012;13:823–31.PubMedCentralPubMedCrossRef Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol. 2012;13:823–31.PubMedCentralPubMedCrossRef
14.
go back to reference Maruyama K, Kawagoe T, Kondo T, Akira S, Takeuchi O. TRAF family member-associated NF-kappaB activator (TANK) is a negative regulator of osteoclastogenesis and bone formation. J Biol Chem. 2012;287:29114–24.PubMedCrossRef Maruyama K, Kawagoe T, Kondo T, Akira S, Takeuchi O. TRAF family member-associated NF-kappaB activator (TANK) is a negative regulator of osteoclastogenesis and bone formation. J Biol Chem. 2012;287:29114–24.PubMedCrossRef
15.
go back to reference Zhou F, Zhang X, Van Dam H, Ten Dijke P, Huang H, Zhang L. Ubiquitin-specific protease 4 mitigates toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem. 2012;287:11002–10.PubMedCrossRef Zhou F, Zhang X, Van Dam H, Ten Dijke P, Huang H, Zhang L. Ubiquitin-specific protease 4 mitigates toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem. 2012;287:11002–10.PubMedCrossRef
16.
go back to reference Hamidi A, Von BV, Hamidi R, et al. Polyubiquitination of transforming growth factor beta (TGFbeta)-associated kinase 1 mediates nuclear factor-kappaB activation in response to different inflammatory stimuli. J Biol Chem. 2012;287:123–33.PubMedCrossRef Hamidi A, Von BV, Hamidi R, et al. Polyubiquitination of transforming growth factor beta (TGFbeta)-associated kinase 1 mediates nuclear factor-kappaB activation in response to different inflammatory stimuli. J Biol Chem. 2012;287:123–33.PubMedCrossRef
17.
go back to reference Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in a luciferase-labeled orthotopic mouse model. Hepatology. 2011;53:483–92.PubMedCrossRef Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in a luciferase-labeled orthotopic mouse model. Hepatology. 2011;53:483–92.PubMedCrossRef
Metadata
Title
TRAF6 promoted the metastasis of esophageal squamous cell carcinoma
Authors
Qingqi Han
Feng Yao
Chenxi Zhong
Heng Zhao
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1098-z

Other articles of this Issue 1/2014

Tumor Biology 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine